• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Finerenone may lower risk of chronic kidney disease progression and cardiovascular events

byHarsh ShahandDeepti Shroff Karhade
November 16, 2020
in Cardiology, Chronic Disease, Endocrinology, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Finerenone treatment lowered the risk of chronic kidney disease (CKD) progression in patients diagnosed with type 2 diabetes and advanced CKD.

2. Treatment with finerenone also lowered the risk of cardiovascular events in patients diagnosed with type 2 diabetes and advanced CKD.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The leading cause of chronic kidney disease (CKD) is type 2 diabetes. Guidelines suggest that the management of CKD in patients diagnosed with type 2 diabetes should include controlling hypertension, hyperglycemia, and the use of a renin-angiotensin system (RAS) blocker. However, despite these recommendations, these patients still possess the risk of CKD progression. A new treatment using finerenone, a nonsteroidal, selective mineralcorticoid receptor antagonist, can reduce urinary albumin-to-creatinine ratio in patients with CKD previously treated with a RAS blocker. As such, this study tested the efficacy of finerenone to slow CKD progression and reduce cardiovascular events in patients diagnosed with advanced CKD and type 2 diabetes. The study concluded that finerenone treatment lowered the risk of CKD progression and cardiovascular events within the treated population. The randomized control trial was limited by the racial demographics of the study population. Since less than 5% of participants identified themselves as Black, the generalizability of the results is restricted. Nonetheless, this study’s results are significant, and its findings highlight the benefit of a therapy to preserve kidney function.

Click to read the study in NEJM

Relevant Reading: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

In-Depth [randomized controlled trial]: This randomized control trial enrolled 5,734 participants in a multicenter study in 48 countries. Participants included in the study were ≥18 years of age, diagnosed with type 2 diabetes and CKD, and treated with a RAS inhibitor at the maximum dose. Participants with a serum potassium level greater than 4.8 mmol per liter were excluded from this study. The participants were randomized in a 1:1 ratio to receive oral, 20 mg, once daily dose of finerenone or placebo, respectively. The primary end point was a composite of kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease of at least 40% for at least 4 weeks, or death from renal causes. Kidney failure was defined as end-stage kidney disease or and eGFR of less than 15 mL per minute per 1.73m2. The median follow-up for the trial was 2.6 years, but 822 participants in the finerenone group (29.0%) and 801 participants in the control group (28.2%) discontinued the trial regimen. The incidence of the primary end point occurred in 504 participants in the finerenone group (17.8%) compared to 600 participants in the control group (21.1%). The incidence of the primary end point was significantly lower in the finerenone group compared to the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P=0.001). The absolute between-group difference was 3.4 percentage points (95% CI, 0.6 to 6.2), and the number of participants requiring finerenone treatment to prevent one primary outcome was 29 (95% CI, 16 to 166). Additionally, death from cardiovascular causes, nonfatal myocardial infarctions, nonfatal stroke, or hospitalization for heart failure occurred in 367 participants in the finerenone group (13.0%) compared to 420 participants in the placebo group (14.8%). The risk for cardiovascular events was significantly lower in the finerenone group compared to the control group (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P=0.03). Finally, the serious adverse events incidence was similar between both groups (finerenone group, 31.9%; placebo group, 34.3%). Specifically, hyperkalemia-related adverse events were twice as frequent in the finerenone group (18.3%) compared to the placebo group (9.0%), and the frequency of hyperkalemia leading to treatment discontinuation was higher in the finerenone group (2.3%) compared to the placebo group (0.9%). Taken together, finerenone treatment lowered the risk of CKD progression and cardiovascular events in participants diagnosed with type 2 diabetes and advanced CKD.

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

Unsweetened coffee consumption is associated with reduced risk of mortality

Uric acid-lowering therapy not associated with improved kidney function

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasechronic kidney disease (CKD)diabetes mellitusfinerenone
Previous Post

Comparison of life and healthy life expectancies between IBD patients and the general population

Next Post

#Visual Abstract: Association between anticoagulation, bleeding, and subsequent cancer diagnoses for patients with atrial fibrillation

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Uric acid-lowering therapy not associated with improved kidney function

June 13, 2022
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

June 18, 2022
Next Post
#VisualAbstract: Adjuvant radiotherapy may worsen outcomes compared to salvage radiotherapy post radical prostatectomy

#Visual Abstract: Association between anticoagulation, bleeding, and subsequent cancer diagnoses for patients with atrial fibrillation

Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Higher SARS-CoV-2 antibody titers in patients hospitalized with MIS-C

Compliance-linked incentives increase infant immunizations rates in rural India

RSV vaccination in third trimester associated with significantly reduced infection risk in early months of life

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.